ADHD 2023 - Congress Programme

18 SCIENTIFIC PROGRAMME Thursday, 18 May 2023 HT-05-003 The results from the Matrics project D. Coghill, Australia HT-05-004 Response to ADHD medication in subjects with autism spectrum disorders N. Adamo, United Kingdom HT-05-005 Alessandro´s legacy – Future Avenues D. Coghill, Australia HT-06 Hot Topic Session 15:00–16:30 G107 Advancing the understanding of ADHD treatment dis- continuity using real-world data Chairs: Z. Chang, Sweden D. Demontis, Denmark HT-06-001 ADHD treatment discontinuation across the lifespan: A multi-national study K. Klungsøyr, Norway HT-06-002 Adherence of ADHD medication and phar- macological treatment for cardiovascular disease Z. Chang, Sweden HT-06-003 Remote measurement technology data on real-world treatment response to ADHD medication in adults with ADHD follow- ing initiation of medication H. Denyer, United Kingdom HT-06-004 Genetic loci and polygenic architecture of simulant ADHD medication discon- tinuation D. Demontis, Denmark YS-01 Young Scientists’ Session 15:00–16:30 G109 Young Scientists´ Session I Chairs: K. Lesch, Germany P. Riederer, Germany YS-01-001 ADHD medications and long-term risk of cardiovascular diseases: A nationwide nested case-control study in Sweden L. Zhang, Sweden YS-01-002 The use of ADHD medication and the risk of suicide attempt: A multinational population-based self-controlled case series study A. Chan YS-01-003 New genes identified associated with ADHD pharmacological treatment re- sponse using both GWAS and deep learning Y. Zhao, China YS-01-004 Assessing brain iron and its relationship to cognition in children with ADHD with quantitative susceptibility mapping M. Schulze, Germany LN-01 Late Breaking News 16:30–17:00 Auditorium Lounge Treatment Outcomes of Stimulant Dose for Adults with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis Introducer: Guilherme Polanczyk, Brazil Interviewers: A. Caye, Brazil; K. Ellison, USA HT-07 Hot Topic Session 17:00–18:30 Auditorium Update on psychopharmacology of ADHD over the life span Chairs: S. Cortese, United Kingdom J. Newcorn, USA HT-07-001 Emerging therapies in the ADHD arma- mentarium J. Newcorn, USA HT-07-002 Neural markers of methylphenidate re- sponse A. Arnett, USA HT-07-003 Evidence-informed approach to managing psychostimulant-refractory ADHD S. Cortese, United Kingdom HT-07-004 Does the liberal or the restrictive clinical policy on ADHD medication provide the best long-term outcomes for patients? B. Brinchmann, Norway HT-08 Hot Topic Session 17:00–18:30 G102-103 Measurement based care in ADHD: Why this approach is relevant for clinicians? Chairs: D. Coghill, Australia S. Faraone, USA HT-08-001 Harmonizing transdiagnostic assessment data for neurodevelopmental disorders A. Guastella, Australia